Neurocrine Biosciences | NBIX - 债务



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 17.6M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 415.3M
EBIT
USD 227.9M
EBITDA
USD 218.4M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 787.9M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 13.39B
净收入
USD 153.7M
营业费用
USD 577.6M
营业利润
USD 227.9M
普通股股本
USD 100.1M
PE价格收益
835.47
税前利润
USD 239.4M
销售收入
USD 811M
销售和管理费用
USD 301.8M
股票
USD 64.5M
贸易债权人
USD 545.5M
应收帐款人
USD 686.8M


债务 更改 日
AbbVie USD 67.5B 67.5B 2025-12
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
ALKERMES USD 70M 1.6M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amgen USD 54.6B 17M 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 605.86M 1.62M 2025-12
Cytokinetics USD 1.28B 87.39M 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Exelixis USD 173.04M 3.42M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 415.3M 13.1M 2025-12
Pfizer USD 63.96B 3.11B 2025-12
Prothena USD 9.08M 699K 2025-09
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Repligen USD 542.21M 146.65M 2025-12
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Teva Pharmaceutical Industries USD 17.09B 21M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 2.03B 195.7M 2025-12
Xoma USD 120.79M 3.27M 2024-06